Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alivus Life SciencesNSE:ALIVUS +0.62%86 Return-on-Tangible-Equity is 19.70% as of Mar. 2026, which is 25% below its 10-year median of 26.23. GuruFocus rates NSE:ALIVUS with a GF Score™ of 86/100 and a GF Value™ of ₹1,018.04 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 901 Drug Manufacturers companies, Alivus Life Sciences ranks better than 76.58% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Alivus Life Sciences's annualized net income for the quarter that ended in Mar. 2026 was ₹6,506 Mil. Alivus Life Sciences's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹33,022 Mil. Therefore, Alivus Life Sciences's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 19.70%.
The historical rank and industry rank for Alivus Life Sciences's Return-on-Tangible-Equity or its related term are showing as below:
NSE:ALIVUS'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 18.51 Med: 26.23 Max: 357.9
Current: 18.62
During the past 8 years, Alivus Life Sciences's highest Return-on-Tangible-Equity was 357.90%. The lowest was 18.51%. And the median was 26.23%.
NSE:ALIVUS's Return-on-Tangible-Equity is ranked better than 76.58% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs NSE:ALIVUS: 18.62
Alivus Life Sciences (NSE:ALIVUS) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Alivus Life Sciences Return-on-Tangible-Equity Related Terms
Alivus Life Sciences Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Alivus Life Sciences's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alivus Life Sciences Return-on-Tangible-Equity Chart
NSE:ALIVUS vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alivus Life Sciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alivus Life Sciences Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alivus Life Sciences's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Alivus Life Sciences's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 19.70% mean?
Alivus Life Sciences (NSE:ALIVUS) has a Return-on-Tangible-Equity of 19.70% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Alivus Life Sciences and its competitors. This is 25% below median its historical median of 26.23. Over the past decade, Alivus Life Sciences' Return-on-Tangible-Equity has ranged from 18.51 to 357.90. According to the industry distribution chart, Alivus Life Sciences ranks #211 out of 901 companies in the Drug Manufacturers industry, placing it in the top 23.4%.
Is Alivus Life Sciences' Return-on-Tangible-Equity too high?
Alivus Life Sciences' current Return-on-Tangible-Equity of 19.70% is 25% below median its 10-year median of 26.23. Over the past 10 years, this metric has ranged from a low of 18.51 to a high of 357.90. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Alivus Life Sciences' value of 19.70% is 149.4% above this industry median. Based on the distribution chart, Alivus Life Sciences ranks #211 out of 901 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Alivus Life Sciences has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alivus Life Sciences' Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Alivus Life Sciences ranks #211 out of 901 companies for Return-on-Tangible-Equity. This places Alivus Life Sciences in the top 23% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.90. Alivus Life Sciences' value of 19.70% is 149.4% above this benchmark. Historically, Alivus Life Sciences' own Return-on-Tangible-Equity has ranged from 18.51 to 357.90 over the past decade. While the company's 10-year median is 26.23 vs. the industry median of 7.90, Alivus Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alivus Life Sciences's current Return-on-Tangible-Equity of 19.70% is 149.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Alivus Life Sciences and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alivus Life Sciences's current Return-on-Tangible-Equity is 19.70%, which is 25% below median its own 10-year median of 26.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alivus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Alivus Life Sciences (NSE:ALIVUS) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,018.04, compared to a current price of ₹1,168.40 — trading 14.8% above its estimated fair value. The current Return-on-Tangible-Equity is 19.70%, which is 25% below median its 10-year median of 26.23 and 149.4% above the Drug Manufacturers industry median of 7.90. Alivus Life Sciences' overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Alivus Life Sciences (NSE:ALIVUS), the current Return-on-Tangible-Equity is 19.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alivus Life Sciences (NSE:ALIVUS) Overvalued in 2026?
Based on GuruFocus' analysis, Alivus Life Sciences stock appears to be overvalued.
The current stock price of ₹1,168.40 is trading 14.8% above its estimated GF Value™ of ₹1,018.04.
GuruFocus considers Alivus Life Sciences to be Modestly Overvalued.
Key valuation signals for NSE:ALIVUS:
Return-on-Tangible-Equity: 19.70% (25% below median its 10-year median of 26.23)
GF Value™: ₹1,018.04 vs. price of ₹1,168.40 (14.8% above fair value)
Industry Position: 149.4% above the Drug Manufacturers median (#211 of 901)
No single metric tells the full story. See the NSE:ALIVUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alivus Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disorders, pain management, diabetes, urology, gastrointestinal disorders, and other therapeutic areas.
86GF Score
Get the complete analysis for NSE:ALIVUS
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ALIVUS has been successfully added to your 
